vs
Copart（CPRT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Copart的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Copart净利率更高（35.0% vs 12.7%，领先22.2%），Revvity同比增速更快（5.9% vs 0.7%），Copart自由现金流更多（$427.2M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.4%）
Copart是一家跨国在线车辆拍卖及再营销服务提供商，服务保险、租车、车队、金融公司等各类汽车经销商，业务覆盖美国、加拿大、英国、德国等11个国家。总部位于美国得克萨斯州达拉斯，拥有200多处实体网点，运营总面积超1万英亩的车辆存放场地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CPRT vs RVTY — 直观对比
营收规模更大
CPRT
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出5.1%
0.7%
净利率更高
CPRT
高出22.2%
12.7%
自由现金流更多
CPRT
多$265.4M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $403.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 37.3% | 14.5% |
| 净利率 | 35.0% | 12.7% |
| 营收同比 | 0.7% | 5.9% |
| 净利润同比 | 11.5% | 3.9% |
| 每股收益（稀释后） | $0.41 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRTRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润CPRTRVTY
| Q4 25 | $403.7M | $98.4M | ||
| Q3 25 | $396.4M | $46.7M | ||
| Q2 25 | $406.6M | $53.9M | ||
| Q1 25 | $387.4M | $42.2M | ||
| Q4 24 | $362.1M | $94.6M | ||
| Q3 24 | $322.6M | $94.4M | ||
| Q2 24 | $382.3M | $55.4M | ||
| Q1 24 | $325.6M | $26.0M |
毛利率CPRTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CPRTRVTY
| Q4 25 | 37.3% | 14.5% | ||
| Q3 25 | 36.7% | 11.7% | ||
| Q2 25 | 37.3% | 12.6% | ||
| Q1 25 | 36.6% | 10.9% | ||
| Q4 24 | 35.4% | 16.3% | ||
| Q3 24 | 33.6% | 14.3% | ||
| Q2 24 | 38.8% | 12.4% | ||
| Q1 24 | 37.2% | 6.8% |
净利率CPRTRVTY
| Q4 25 | 35.0% | 12.7% | ||
| Q3 25 | 35.2% | 6.7% | ||
| Q2 25 | 33.6% | 7.5% | ||
| Q1 25 | 33.3% | 6.4% | ||
| Q4 24 | 31.6% | 13.0% | ||
| Q3 24 | 30.2% | 13.8% | ||
| Q2 24 | 33.9% | 8.0% | ||
| Q1 24 | 31.9% | 4.0% |
每股收益（稀释后）CPRTRVTY
| Q4 25 | $0.41 | $0.86 | ||
| Q3 25 | $0.40 | $0.40 | ||
| Q2 25 | $0.42 | $0.46 | ||
| Q1 25 | $0.40 | $0.35 | ||
| Q4 24 | $0.37 | $0.77 | ||
| Q3 24 | $0.34 | $0.77 | ||
| Q2 24 | $0.39 | $0.45 | ||
| Q1 24 | $0.33 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.6B | $7.3B |
| 总资产 | $10.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRTRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务CPRTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $427.0K | — | ||
| Q1 24 | $453.0K | — |
股东权益CPRTRVTY
| Q4 25 | $9.6B | $7.3B | ||
| Q3 25 | $9.2B | $7.4B | ||
| Q2 25 | $8.8B | $7.6B | ||
| Q1 25 | $8.3B | $7.6B | ||
| Q4 24 | $7.9B | $7.7B | ||
| Q3 24 | $7.5B | $7.9B | ||
| Q2 24 | $7.2B | $7.9B | ||
| Q1 24 | $6.8B | $7.8B |
总资产CPRTRVTY
| Q4 25 | $10.6B | $12.2B | ||
| Q3 25 | $10.1B | $12.1B | ||
| Q2 25 | $9.7B | $12.4B | ||
| Q1 25 | $9.2B | $12.4B | ||
| Q4 24 | $8.9B | $12.4B | ||
| Q3 24 | $8.4B | $12.8B | ||
| Q2 24 | $8.0B | $13.4B | ||
| Q1 24 | $7.6B | $13.4B |
负债/权益比CPRTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $535.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $427.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 37.0% | 21.0% |
| 资本支出强度资本支出/营收 | 9.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.33× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.4B | $509.4M |
8季度趋势，按日历期对齐
经营现金流CPRTRVTY
| Q4 25 | $535.3M | $182.0M | ||
| Q3 25 | $438.5M | $138.5M | ||
| Q2 25 | $700.9M | $134.3M | ||
| Q1 25 | $178.1M | $128.2M | ||
| Q4 24 | $482.3M | $174.2M | ||
| Q3 24 | $439.2M | $147.9M | ||
| Q2 24 | $496.3M | $158.6M | ||
| Q1 24 | $161.8M | $147.6M |
自由现金流CPRTRVTY
| Q4 25 | $427.2M | $161.8M | ||
| Q3 25 | $350.8M | $120.0M | ||
| Q2 25 | $572.9M | $115.5M | ||
| Q1 25 | $61.5M | $112.2M | ||
| Q4 24 | $245.5M | $149.8M | ||
| Q3 24 | $301.3M | $125.6M | ||
| Q2 24 | $408.5M | $136.6M | ||
| Q1 24 | $38.8M | $129.7M |
自由现金流率CPRTRVTY
| Q4 25 | 37.0% | 21.0% | ||
| Q3 25 | 31.2% | 17.2% | ||
| Q2 25 | 47.3% | 16.0% | ||
| Q1 25 | 5.3% | 16.9% | ||
| Q4 24 | 21.4% | 20.5% | ||
| Q3 24 | 28.2% | 18.4% | ||
| Q2 24 | 36.2% | 19.7% | ||
| Q1 24 | 3.8% | 20.0% |
资本支出强度CPRTRVTY
| Q4 25 | 9.4% | 2.6% | ||
| Q3 25 | 7.8% | 2.6% | ||
| Q2 25 | 10.6% | 2.6% | ||
| Q1 25 | 10.0% | 2.4% | ||
| Q4 24 | 20.6% | 3.4% | ||
| Q3 24 | 12.9% | 3.3% | ||
| Q2 24 | 7.8% | 3.2% | ||
| Q1 24 | 12.1% | 2.7% |
现金转化率CPRTRVTY
| Q4 25 | 1.33× | 1.85× | ||
| Q3 25 | 1.11× | 2.97× | ||
| Q2 25 | 1.72× | 2.49× | ||
| Q1 25 | 0.46× | 3.03× | ||
| Q4 24 | 1.33× | 1.84× | ||
| Q3 24 | 1.36× | 1.57× | ||
| Q2 24 | 1.30× | 2.87× | ||
| Q1 24 | 0.50× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRT
| Services | $952.1M | 82% |
| Other | $203.0M | 18% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
